gynecology-breast-pathology-2019-keynote

3 / 8

June 28-29, 2019 | Oslo, Norway
Page 26
Journal of Medical and Health Sciences | ISSN : 2319-9865
Joint Event
Volume 08 Breast Pathology & Cancer, Gynecology & Obstetrics Pathology, Palliativecare & Gerontology 2019
Breast Pathology & Cancer Palliativecare & Gerontology Gynecology and Obstetrics Pathology
Should we use the term “borderline breast disease”
instead of low grade ductal carcinoma in-situ in breast
core needle biopsy?
During the last several years, increased public awareness, advances in
breast imaging and enhanced screening programs have led to early
breast cancer detection and attention to cancer prevention. The numbers
of image-detected biopsies have increased and pathologists are expected to
provide more information with smaller tissue samples. These biopsies have
resulted in detection of increasing numbers of high-risk proliferative breast
disease and in-situ cancers. The general hypothesis is that some forms of
breast cancers may arise from established forms of ductal carcinoma in-
situ (DCIS) and atypical ductal hyperplasia (ADH) and possibly frommore
common forms of ductal hyperplasia. However, this is an oversimplification
of a very complex process, given the fact that the majority of breast cancers
appears to arisede-novo or from a yet unknown precursor lesion. Currently,
ADH and DCIS are considered as morphologic risk factors and precursor
lesions for breast cancer. However, morphologic distinction between these
two entities has remained a real issue that continues to lead to overdiagnoses
and overtreatment. Aside frommorphologic similarities between ADH and
low grade DCIS, biomarker studies and molecular genetic testings have
shown that morphologic overlaps are reflected at the molecular levels and
raise questions about the validity of separating these two entities. It is hoped
that as we better understand the genetic basis of these entities in relation
to ultimate patient outcome, the suggested use of the term of “borderline
breast disease” can minimize the number of patients who are subjected to
overtreatment.
Biography
Shahla Masood is a Persian born Physician, who currently holds the positions of Professor and
Chair of the Department of Pathology at University of Florida College of Medicine – Jacksonville
and Chief of Pathology and Laboratory Medicine at UF Health Jacksonville. She is also the Director
of the Cytopathology and Breast Pathology Fellowship Training Program and Medical Director
of UF Health Breast Center. An internationally recognized expert in breast cancer diagnosis and
prognosis, she has fostered the concept of an integrated multidisciplinary approach in breast
cancer care, research, and education. She is the Founder and Editor-in-Chief of The Breast
Journal, the Founder and past President of the “International Society of Breast Pathology,” the
Director of the “Annual Multidisciplinary Symposium on Breast Disease”, and “The Breast Cancer
Public Forum”. She is heavily involved in the study of minimally invasive procedures such as fine
needle aspiration biopsy and ductal lavage in providing diagnostic and prognostic information in
high risk and breast cancer patients.”
Shahla Masood
University of Florida College of
Medicine – Jacksonville, USA
Shands Jacksonville Breast Health
Center, USA
Shahla Masood, RRJMHS 2019, Volume 08